Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback